Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension

NCT03789643 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Corporate decision, priority change

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: JTT-251
DRUG: Placebo

Sponsor

Akros Pharma Inc.